UPDATE: KeyBanc On Colfax Price Target Raise: Firm Encouraged By 'Sustained Momentum In FabTech & Anticipates MedTech Margins To Improve' As Elective Surgery Rates Normalize; Notes Auto Demand Lagging But Able To Drive Incremental Upside Into FY22